Navigation Links
Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson
Date:10/2/2013

MONTREAL y EMERYVILLE, California, 2 de octubre de 2013 /PRNewswire-HISPANIC PR WIRE/ -- Adamas Pharmaceuticals, Inc. presentó hoy resultados positivos de la prueba clínica EASED™ Fase 2/3 de ADS-5102 en el Congreso Mundial del Parkinson.  ADS-5102 es la formulación patentada de cápsula de acción prolongada de amantadina HCl de Adamas en desarrollo para el tratamiento de la disquinesia inducida por levodopa (LID por sus siglas en inglés) en pacientes de la enfermedad de Parkinson (PD por sus siglas en inglés).  ADS-5102 alcanzó su punto final primario en la prueba clínica de Fase 2/3 y demostró mejoras estadísticamente significativas en varias evaluaciones claves de la LID.

(Logo:  http://photos.prnewswire.com/prnh/20130618/LA33709LOGO)

"Estamos sumamente complacidos con los resultados positivos logrados en nuestra prueba EASED Fase 2/3, y con la magnitud del cambio en el período de respuesta a los medicamentos sin disquinesia molesta en pacientes de Parkinson que padecen de LID.  La disquinesia inducida por levodopa es uno de los retos más difíciles que afrontan los pacientes de PD, y no hay tratamientos con fármacos aprobados por la FDA disponibles", dijo Gregory T. Went, Ph.D., director ejecutivo de Adamas. "ADS-5102 redujo tanto la duración como la severidad de la disquinesia en pacientes de PD con significación estadística, proporcionando un promedio de 11.5 horas durante el día de período de respuesta a los medicamentos sin disquinesia molesta, en comparación con 8 horas con placebo.  Los alentadores datos de esta prueba indican que ADS-5102 tiene el potencial de ejercer un impacto positivo en la vida de los pacientes de la PD y estamos avanza
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
2. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
3. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
4. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
5. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
6. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
7. Inovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor Forum
8. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
9. Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States
10. Industry Landscape Opens Doors for GeoBargain Polydex Pharmaceuticals
11. Prolong Pharmaceuticals Presents Novel Multi-Pronged Approach To Treating Sickle Cell Disease At The SCDAA Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 /PRNewswire-iReach/ -- Dan York has been ... of the RTD ® Advanced Wound Care Dressing, ... sales presence in the U.S. Under York,s leadership, GWM ... field sales representatives in new sales territories that will ... add up to 20 sales representatives in major metropolitan ...
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... , Sept. 16, 2014  Advanced Medical ... stage development company engaged primarily in the ... for diagnostic and therapeutic applications, today announced ... related to its brachytherapy products.  AMIC,s rights ... its license from Battelle, under which AMIC ...
Breaking Medicine Technology:GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... IRVINE, Calif., June 12 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, announced today that three ... of Masimo PVI as a noninvasive and continuous measure ... week at the European Society of Anaesthesiology (ESA) Annual ...
... Safety and Biologic Activity Data Reviewed in End of Phase ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular and metabolic disease, announced today that an ... VIA-2291 (atreleuton), was recently held with the U.S. Food and ...
Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
(Date:9/16/2014)... September 16, 2014 Advanced Fertility Center ... named by Houstonia Magazine as one of the Top ... Houstonia Magazine - a metropolitan magazine serving the Houston ... and recognize them for their outstanding services. This accomplishment ... edition of Houstonia Magazine — a special publication listing ...
(Date:9/16/2014)... These new programs allow those who haven’t owned a ... $10,000 in a 0% interest free, 2nd down payment assistance ... federal programs, are listed on their private website. The $10,000 ... or move out of the property. The down payment assistance ... no monthly payments paid by the Borrower. The money is ...
(Date:9/16/2014)... Aspen Advisors, a U.S.-based healthcare IT ... for its high morale and collaborative culture ... Firms to Work For 2014.” Consulting magazine publishes ... 10,000 consultants participating across all major industries, representing more ... conducted, and firms were ranked in six categories - ...
(Date:9/16/2014)... 14, 2014 A new clinical trial ... and drug-eluting balloons (DEB) in treating in-stent ... EES provided superior late angiographic results and ... were reported today at the 26th annual ... by the Cardiovascular Research Foundation (CRF), TCT ...
(Date:9/16/2014)... Ensuring that corn absorbs the right balance of nitrogen, ... a Purdue and Kansas State University study finds. , ... from the U.S. and other regions showed that high ... plants took up key nutrients at specific ratios - ... nitrogen and potassium at a ratio of 1-to-1. These ...
Breaking Medicine News(10 mins):Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Results of RIBS IV trial reported at TCT 2014 2Health News:Boosting global corn yields depends on improving nutrient balance 2Health News:Boosting global corn yields depends on improving nutrient balance 3
... Optical technology is as accurate as colorectal tissue examination, ... Optical technology could help physicians detect small colorectal polyps ... , In the report, published online Nov. 10 in ... that the technique could replace histopathology, which requires more ...
... cancer has eliminated tumours in 50% of mice in a new ... the animals, the drug also stopped lung cancer tumours from growing ... Imperial College London, are now planning to take the drug into ... with an inoperable form of lung cancer. One in five ...
... 10 Reportlinker.com announces that a new ... catalogue. , Central Nervous System ... http://www.reportlinker.com/p0161866/Central-Nervous-System-Insomnia-or-Sleep-Disorders.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , Life ... Sleep Disorders contains detailed information on the ...
... Hospital Dallas is the first hospital in Dallas and one ... Cycle III Chest Pain Center by the Society of Chest ... , "This honor means that Texas Health Presbyterian Dallas ranks ... collaborative treatment of heart attacks," said cardiologist Dr. John Harper, ...
... estimates 2,266 U.S. military veterans under the age of 65 died ... access to care. That figure is more than 14 times the ... 2008, and more than twice as many as have died (911 ... The researchers, who released their analysis today, pointedly say the health ...
... But researchers not exactly sure how pathogens raise risk of ... to several common pathogens may increase the risk of having ... Mitchell Elkind, an associate professor of neurology at Columbia University ... that the pathogens Chlamydia pneumoniae , Helicobacter pylori ...
Cached Medicine News:Health News:New Polyp Detection Method Could Be Cost-Saver 2Health News:Drug shrinks lung cancer tumors in mice 2Health News:Drug shrinks lung cancer tumors in mice 3Health News:Reportlinker Adds Central Nervous System Insomnia or Sleep Disorders 2Health News:Reportlinker Adds Central Nervous System Insomnia or Sleep Disorders 3Health News:Texas Health Dallas Receives Prestigious Chest Pain Accreditation 2Health News:Over 2,200 veterans died in 2008 due to lack of health insurance 2Health News:Common Infections May Contribute to Strokes 2Health News:Common Infections May Contribute to Strokes 3
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Micro emulsifying needles, 18G....
Micro 2000, micro scissors micro 2000 supercut....
Yasargil clip applying forceps Mini. Stainless steel jaw....
Medicine Products: